PE20040916A1 - Diamidas de acido pirimidin-4,6-dicarboxilico como inhibidores selectivos de mmp-13 - Google Patents

Diamidas de acido pirimidin-4,6-dicarboxilico como inhibidores selectivos de mmp-13

Info

Publication number
PE20040916A1
PE20040916A1 PE2003001280A PE2003001280A PE20040916A1 PE 20040916 A1 PE20040916 A1 PE 20040916A1 PE 2003001280 A PE2003001280 A PE 2003001280A PE 2003001280 A PE2003001280 A PE 2003001280A PE 20040916 A1 PE20040916 A1 PE 20040916A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrimidin
halogen
substituted
mmp
Prior art date
Application number
PE2003001280A
Other languages
English (en)
Inventor
Otmar Klingler
Reinhard Kirsch
Jorg Habermann
Klaus-Ulrich Weithmann
Christian Engel
Bernard Pirard
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20040916A1 publication Critical patent/PE20040916A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

SE REFIERE A DIAMIDAS DE ACIDO PIRIMIDIN-4,6-DICARBOXILICO DE FORMULA I DONDE R1 ES H O ALQUILO C1-C6; R2 ES ALQUILO C1-C6 SUSTITUIDO UNA A TRES VECES POR C(O)-O-R8, ALQUIL(C1-C6)-O-R8, ENTRE OTROS; R3, R4, R5, R6 y R7 SON H, HALOGENO, ALQUILO C1-C6 NO SUSTITUIDO O SUSTITUIDO HASTA TRES VECES POR HALOGENO, O-ALQUILO C1-C6 NO SUSTITUIDO O SUSTITUIDO HASTA TRES VECES POR HALOGENO, S-ALQUILO C1-C6; R8 ES H O ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS: [4-({[6-(4-FLUORO-3-METILBENCILCARBAMOIL)-PIRIMIDIN-4-CARBONIL]AMINO}METIL)FENOXI] ACETATO DE TERC-BUTILO; ACIDO [4-({[6-(4-FLUORO-3-METILBENCILCARBAMOIL)-PIRIMIDIN-4-CARBONIL]AMINO}METIL)FENOXI] ACETICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA PREPARAR ESTOS COMPUESTOS Y UN PRODUCTO FARMACEUTICO. ESTOS COMPUESTOS SON UTILES PARA LA PROFILAXIS Y LA TERAPIA DE ENFERMEDADES CUYO CURSO IMPLICA UNA ACTIVIDAD INCREMENTADA DE METALOPROTEINASA DE MATRIZ 13 COMO SON ENFERMEDADES DEGENERATIVAS DE LAS ARTICULACIONES, ENFERMEDADES DEL TEJIDO CONECTIVO, ENFERMEDADES CANCEROSAS
PE2003001280A 2003-01-03 2003-12-12 Diamidas de acido pirimidin-4,6-dicarboxilico como inhibidores selectivos de mmp-13 PE20040916A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10300017A DE10300017A1 (de) 2003-01-03 2003-01-03 Selektive MMP 13 Inhibitoren

Publications (1)

Publication Number Publication Date
PE20040916A1 true PE20040916A1 (es) 2005-01-25

Family

ID=32519591

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001280A PE20040916A1 (es) 2003-01-03 2003-12-12 Diamidas de acido pirimidin-4,6-dicarboxilico como inhibidores selectivos de mmp-13

Country Status (11)

Country Link
EP (1) EP1587803A1 (es)
JP (1) JP2006515595A (es)
AR (1) AR042687A1 (es)
AU (1) AU2003293951A1 (es)
BR (1) BR0317834A (es)
CA (1) CA2512183A1 (es)
DE (1) DE10300017A1 (es)
MX (1) MXPA05006401A (es)
PE (1) PE20040916A1 (es)
TW (1) TW200505906A (es)
WO (1) WO2004060883A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
US20070155737A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
JP2009522295A (ja) * 2005-12-30 2009-06-11 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド 置換ビス−アミドメタロプロテアーゼ阻害剤
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP2094707A1 (en) * 2006-11-20 2009-09-02 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic matrix metalloprotease inhibitors
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG10201505700QA (en) 2010-04-22 2015-08-28 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
SI3131582T1 (sl) 2014-04-15 2018-09-28 Vertex Pharmaceuticals Incorporated Farmacevtski sestavki za zdravljenje bolezni, pri katerih posreduje regulator transmembranske prevodnosti
GB201908453D0 (en) * 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931432A1 (de) * 1989-09-21 1991-04-04 Hoechst Ag Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen
DE60236851D1 (en) * 2001-02-14 2010-08-12 Warner Lambert Co Pyrimidinmatrixmetalloproteinaseinhibitoren
DE10160357A1 (de) * 2001-12-08 2003-06-18 Aventis Pharma Gmbh Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen

Also Published As

Publication number Publication date
TW200505906A (en) 2005-02-16
WO2004060883A1 (de) 2004-07-22
MXPA05006401A (es) 2005-08-19
AU2003293951A1 (en) 2004-07-29
DE10300017A1 (de) 2004-07-15
EP1587803A1 (de) 2005-10-26
BR0317834A (pt) 2005-11-29
JP2006515595A (ja) 2006-06-01
CA2512183A1 (en) 2004-07-22
AR042687A1 (es) 2005-06-29

Similar Documents

Publication Publication Date Title
ME01310B (me) Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa
SE0200979D0 (sv) New compounds
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
SE9903760D0 (sv) New compounds
BRPI0414867A (pt) pirazolopiridinas e seus análogos
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
TW200517109A (en) Substituted pyridinones
RS20070076A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
HRP20050967B1 (hr) Derivati pirazolo-kinazolina, postupak njihovog dobivanja i njihova uporaba kao inhibitora kinaze
NO20012158L (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
CY1109376T1 (el) Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης
PE20040916A1 (es) Diamidas de acido pirimidin-4,6-dicarboxilico como inhibidores selectivos de mmp-13
WO2003063791A3 (en) Non-steroidal analogs of 2-methoxyestradiol
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
EE200200504A (et) Farmatseutilised preparaadid
ATE444069T1 (de) Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom

Legal Events

Date Code Title Description
FC Refusal